Still Refining Adjuvant Endocrine Therapy in Premenopausal Women: Not Too Much, Not Too Little

Affiliations

¹ The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD awolff@jhmi.edu.
² University of California San Francisco Comprehensive Cancer Center, San Francisco, CA.

Editorial

Antonio C Wolff et al. J Clin Oncol. 2016.

. 2016 Jul 1;34(19):2203-5.

doi: 10.1200/JCO.2016.67.0463. Epub 2016 May 16.

¹ The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD awolff@jhmi.edu.
² University of California San Francisco Comprehensive Cancer Center, San Francisco, CA.

No abstract available

Comment on

Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.
Regan MM, Francis PA, Pagani O, Fleming GF, Walley BA, Viale G, Colleoni M, Láng I, Gómez HL, Tondini C, Pinotti G, Price KN, Coates AS, Goldhirsch A, Gelber RD. Regan MM, et al. J Clin Oncol. 2016 Jul 1;34(19):2221-31. doi: 10.1200/JCO.2015.64.3171. Epub 2016 Apr 4. J Clin Oncol. 2016. PMID: 27044936 Free PMC article.